Citi still bullish on Ambit despite no AA for quizartinib 03:03 PM ET · AMBI
Citi maintains a Buy rating on Ambit Biosciences (AMBI -35.2%). Although Citi reportedly says AA for quizartinib wasn't baked into the share price. Price target lowered to $17 from $19.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.